Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine + Durvalumab in Advanced B-Cell Lymphomas
NCT03685344Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- Feb 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL), sponsored by ADC Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Dose-Limiting Toxicity at 21 days and 2 more. Started Feb 2019; status: terminated.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03685344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685344.